Generate Biomedicines (NASDAQ:GENB) Hits New 1-Year High – Here’s Why

Shares of Generate Biomedicines Inc (NASDAQ:GENB) hit a new 52-week high during trading on Tuesday . The stock traded as high as $18.41 and last traded at $18.6240, with a volume of 199688 shares. The stock had previously closed at $17.72.

Wall Street Analyst Weigh In

GENB has been the topic of a number of research analyst reports. Weiss Ratings assumed coverage on shares of Generate Biomedicines in a report on Tuesday, August 11th. They set a “sell (d)” rating on the stock. Wall Street Zen downgraded shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. HC Wainwright upped their target price on shares of Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, Morgan Stanley increased their price target on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Generate Biomedicines Stock Performance

The firm’s fifty day moving average price is $15.05. The firm has a market cap of $2.73 billion and a price-to-earnings ratio of -13.76.

Generate Biomedicines (NASDAQ:GENB) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The company had revenue of $6.31 million during the quarter. Research analysts anticipate that Generate Biomedicines Inc will post -2.29 earnings per share for the current fiscal year.

Institutional Trading of Generate Biomedicines

Hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System bought a new position in shares of Generate Biomedicines during the 2nd quarter worth approximately $96,000. Susquehanna International Group LLP bought a new position in Generate Biomedicines during the second quarter worth $196,000. AXQ Capital LP acquired a new position in shares of Generate Biomedicines in the second quarter valued at $218,000. Bank of New York Mellon Corp bought a new position in shares of Generate Biomedicines in the second quarter valued at about $967,000. Finally, Braidwell LP acquired a new stake in shares of Generate Biomedicines during the 2nd quarter worth about $55,398,000.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.